BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 （股份代號：06160） 員工購股計劃項下的股份購買 本公告乃根據上市規則第17.06A、17.06B以及17.06C條作出。茲提述本公司日期 為2025年3月6日的公告（「該公告」），內容有關董事會於2025年5月27日批准的第 五份經修訂及經重列2018員工購股計劃（「2018員工購股計劃」）項下的認購期自 2025年3月3日至2025年8月29日期間的股份購買。除另有界定者外，本公告所用 詞彙與該公告所定義者具有相同涵義。 關於2018員工購股計劃項下的股份購買的更新 如該公告所披露，2018員工購股計劃使合資格僱員可按市價15%折讓申購股份 （包括以美國存託股份的形式）。僱員可於認購期結束後購買股份，購股資金可從 其認購期內所得薪金中扣除。 公司謹此向其股東告知並宣佈，截至2025年3月3日至2025年8月 ...

Core Viewpoint - The Trump administration is drafting an executive order to impose strict restrictions on Chinese pharmaceuticals, particularly experimental drugs, aiming to curb the rapid development of China's biotech industry, which may negatively impact the U.S. pharmaceutical supply chain and patient access to innovative therapies [1][4]. Group 1: Market Reaction - Following the news, stocks of various pharmaceutical companies, including BeiGene (ONC.US), Zai Lab (ZLAB.US), Legend Biotech (LEGN.US), Pfizer (PFE.US), AstraZeneca (AZN.US), and GlaxoSmithKline (GSK.US), experienced varying degrees of decline [1]. - BeiGene's stock saw a significant drop of up to 12% during intraday trading on September 10, but rebounded by 6.93% by the close on September 11, indicating a quick recovery in market sentiment [1][3]. Group 2: Policy Implications - The proposed executive order includes three main components: threatening to cut off supply channels for Chinese-developed drugs, imposing stricter scrutiny on U.S. pharmaceutical companies purchasing drugs from Chinese firms, and requiring the FDA to conduct more rigorous reviews and charge higher regulatory fees [4]. - The policy may inadvertently harm U.S. multinational pharmaceutical companies (MNCs) as nearly 200 drugs, including 69 blockbuster drugs with annual sales exceeding $1 billion, are set to lose patent protection, leading to a potential $115 billion patent cliff by 2035 [5]. Group 3: Industry Perspectives - Analysts suggest that the proposed restrictions may backfire, as they could limit U.S. biopharmaceutical companies' access to Chinese assets and innovation, which are crucial for maintaining competitive pricing and addressing patent expirations [7][9]. - Major pharmaceutical companies like Pfizer, Merck, and AstraZeneca have voiced support for Chinese biotech firms, recognizing their role in providing cost-effective solutions and rapid delivery capabilities [7]. Group 4: Future Outlook - Despite the recent market volatility, the innovative drug sector remains a favored investment area, with reports indicating that the Hong Kong innovative drug sector turned profitable for the first time in the first half of the year [9]. - Analysts from various firms, including Southwest Securities and CITIC Securities, expect continued growth in the A-share and Hong Kong pharmaceutical sectors, driven by innovation and internationalization [9][10]. - The potential executive order's feasibility is questioned, with some analysts believing it may not be implemented due to existing U.S. pharmaceutical policies [10][11].

智通财经APP讯，百济神州(06160)发布公告，于2025年9月11日因根据第五版经修订及重列的2018员工 购股权计划而发行普通股81.85万股。 ...

百济神州(06160)发布公告，于2025年9月11日因根据第五版经修订及重列的2018员工购股权计划而发行 普通股81.85万股。 ...

百济神州(6160.HK)今日盘中一度涨5.26%至204港元，年内累涨约87%。消息面上，联交所权益披露资料显示，百济神州于9月9日获The Capital Group Companies, Inc.在场内以每股均价348.12港元增持88.26万股，涉资约3.07亿港元。增持后，其持股比例由4.96%上升至5.02%。(格隆汇) | 股份代號: | 06160 | | --- | --- | | 上市法國名稱: | 百濟神州有限公司 | | 日期 (日 / 月 / 年): | 12/08/2025 - 12/ | | 表格序號 | | 大股東/董事/最高行政人員名 | | | 作出披露的 買入 / 賣出或涉及的 | | 每股的平均價 | 持有權益的股份數目 | | 佔已發行的 有關事件的日期相 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 景区 | | 股份數目 | | | (請參閱上述*註 | | 有投票權股 (日 / 月 / 年) | | | | | | | | | | | | 份百分比 % ...

Core Viewpoint - After a significant drop, Hong Kong's innovative drug concept stocks rebounded across the board, indicating market resilience and potential recovery in the sector [1] Group 1: Market Performance - As of the report, Kangning Jereh Pharmaceutical-B surged over 14%, Hutchison China MediTech rose more than 6%, Zai Lab and Lepu Biopharma B increased over 5%, and Akeso-B climbed over 4% [1] Group 2: Industry Sentiment - Several pharmaceutical companies have acknowledged rumors regarding potential restrictions from the U.S. on innovative drugs from China, but they believe these rumors do not currently impact the expectations for Chinese innovative drugs entering international markets [1] Group 3: Future Outlook - Market analysts predict that leading biotech companies such as BeiGene and Innovent Biologics are expected to reach a profitability inflection point by 2025, with a strong growth trajectory anticipated thereafter [1] - With improvements in industrial capabilities and product line expansions, it is expected that more biotech firms will enter a profitability cycle in the future [1]

Core Viewpoint - The A+H innovative drug sector is experiencing a rebound, with significant gains in both A-share and Hong Kong-listed ETFs focused on innovative drugs, indicating strong market confidence despite recent negative news from the U.S. regarding potential restrictions on Chinese pharmaceuticals [1][3]. Market Performance - The Hong Kong innovative drug ETF (520880) has seen a net subscription of over 160 million yuan in a single day, continuing a streak of eight consecutive days of inflows totaling nearly 350 million yuan [3]. - Major players in the Hong Kong innovative drug sector, such as BeiGene and CanSino Biologics, have reported gains exceeding 4%, while smaller companies like Jiateng Biopharma-B have surged over 17% to reach a historical high [1][3]. Industry Trends - The fund manager of the Hong Kong innovative drug ETF (520880) expressed confidence that U.S. restrictions on Chinese innovative drugs are unlikely to be implemented, citing that multinational corporations (MNCs) have already procured over 90 billion USD worth of Chinese innovative drug patents from January to August this year [3][4]. - The ETF has undergone a "purification" adjustment, completely removing CXO companies and focusing solely on innovative drug R&D firms, which is expected to enhance its performance in the sector [4]. Investment Insights - The recent market volatility may present a buying opportunity for high-quality innovative drug stocks, as the ETF is positioned to capitalize on potential rebounds in the sector [4]. - The Hong Kong innovative drug ETF (520880) has achieved a year-to-date increase of 119.75%, outperforming other indices in the same category prior to the recent adjustments [4][5].

Core Insights - China's innovative drug development has achieved significant milestones, with over 20% of global new drug research and development, ranking second globally [1] - The number of approved innovative drugs has accelerated, with 43 new drugs approved in the first half of 2025, marking a historical high for the same period [3][4] - The trend of "innovation + internationalization" in the pharmaceutical industry remains strong, with Chinese companies showing competitive advantages in various therapeutic areas [1][2] Industry Development - During the "14th Five-Year Plan" period, China approved 210 innovative drugs and 269 innovative medical devices, indicating a sustained growth trend [1] - The total amount of foreign licensing for innovative drugs reached nearly $66 billion in the first half of 2025, reflecting increasing global recognition of Chinese innovative drugs [1] - The biopharmaceutical industry is experiencing a resurgence, with significant growth potential remaining, driven by technological advancements and improved global competitiveness [2] Company Performance - Leading innovative pharmaceutical companies have reported strong revenue growth, with Hengrui Medicine achieving a revenue of 15.76 billion yuan, a year-on-year increase of 15.88% [3] - Innovent Biologics turned a profit in the first half of 2025, with a net profit of 1.21 billion yuan, compared to a loss of 160 million yuan in the same period last year [5] - The sales of innovative drugs are becoming a prominent feature of the industry, with companies like BeiGene and Fosun Pharma also reporting significant revenue increases [3][5] Regulatory Environment - The National Medical Products Administration (NMPA) has optimized the clinical trial review and approval process, reducing the review time from 60 days to 30 days [6] - Continuous improvements in the drug approval process are expected to further stimulate innovative drug development [6] R&D Investment - R&D investment among leading pharmaceutical companies has increased, with a total of 17.64 billion yuan spent on R&D in the first half of 2025, a year-on-year increase of 12.66% [7] - Companies like BeiGene and Hengrui Medicine are leading in R&D expenditures, emphasizing the importance of innovation in their growth strategies [7] Market Trends - The oncology drug segment remains the dominant area for innovative drugs, accounting for approximately 40% of the approved drugs [5] - The rapid commercialization of innovative drugs is driving performance breakthroughs for pharmaceutical companies [5][8] - ADC (antibody-drug conjugates) and other advanced therapies are gaining traction, with several companies making significant progress in these areas [9][10]

Core Viewpoint - The article discusses the resilience of the innovative drug sector in the face of negative news and highlights the long-term investment opportunities despite short-term volatility [3][4][9]. Group 1: Market Performance - On September 10, both the A-share and Hong Kong innovative drug sectors opened significantly lower due to negative external news, but many stocks rebounded during the day, demonstrating the sector's resilience [3][4]. - The innovative drug ETF in the A-share market initially dropped over 5.7% but closed down only 0.51%, indicating a recovery [4]. - The total revenue of 39 Hong Kong innovative drug companies reached 152.06 billion yuan in the first half of 2025, a year-on-year increase of 7.66%, with net profit increasing by 54.37% to 28.27 billion yuan [7]. Group 2: Policy Impact and Industry Dynamics - The negative sentiment was triggered by reports of the Trump administration drafting an executive order to impose strict restrictions on Chinese drugs, particularly laboratory drugs [4][6]. - Fund managers believe that the policy direction has already been anticipated and will not have a substantial new impact on the sector [3][4]. - The collaboration between multinational corporations (MNCs) and Chinese innovative drug companies remains strong, as MNCs benefit significantly from introducing Chinese innovations [5][6]. Group 3: Investment Opportunities - The current innovative drug market is driven by improved fundamentals rather than just capital influx, with many companies entering a phase of profit growth [7][9]. - The article suggests focusing on mid-to-large innovative drug companies that have already launched products and are contributing to earnings, as well as those with high certainty in business development [3][9]. - The long-term trend for innovative drugs is expected to continue, with the potential for significant market capitalization growth surpassing previous cycles [7][8]. Group 4: Short-term Risks and Strategies - Despite the resilience of the pharmaceutical sector, fund managers caution about short-term volatility risks due to high market indices and negative sentiment [8][9]. - Historical experience indicates that emotional pullbacks triggered by sudden events can present good buying opportunities [10].

Core Insights - The top three companies by Hong Kong Stock Connect holding ratios are China Telecom (00728) at 72.05%, Green Power Environmental (01330) at 69.19%, and China Shenhua (01088) at 67.94% [1] - Alibaba-W (09988), Horizon Robotics-W (09660), and BYD Company (01211) saw the largest increases in holding amounts over the last five trading days, with increases of +126.42 billion, +37.06 billion, and +23.82 billion respectively [1] - The largest decreases in holding amounts over the last five trading days were recorded by the Tracker Fund of Hong Kong (02800) at -19.72 billion, China Telecom (00728) at -13.62 billion, and Kuaishou-W (01024) at -10.29 billion [1] Hong Kong Stock Connect Latest Holding Ratios - China Telecom (00728): 100.01 billion shares, 72.05% holding ratio [1] - Green Power Environmental (01330): 2.80 billion shares, 69.19% holding ratio [1] - China Shenhua (01088): 22.95 billion shares, 67.94% holding ratio [1] - Other notable companies include Kaisa New Energy (01108) at 67.53% and COSCO Shipping Energy (01138) at 65.47% [1] Recent Increases in Holdings (Last 5 Trading Days) - Alibaba-W (09988): +126.42 billion, +88.22 million shares [1] - Horizon Robotics-W (09660): +37.06 billion, +361.88 million shares [1] - BYD Company (01211): +23.82 billion, +22.64 million shares [1] - Other companies with significant increases include Meituan-W (03690) and Ping An Insurance (02318) [1] Recent Decreases in Holdings (Last 5 Trading Days) - Tracker Fund of Hong Kong (02800): -19.72 billion, -73.80 million shares [3] - China Telecom (00728): -13.62 billion, -233.30 million shares [3] - Kuaishou-W (01024): -10.29 billion, -14.02 million shares [3] - Other companies with notable decreases include Pop Mart (09992) and Meitu (01357) [3]